Everything you wish someone told you about automating RCM
From failed bots to million-dollar recoveries – stories, frameworks, and lessons from the field.
Featured insights
.png)
.png)
.png)
The State of Claim Denials in U.S. Healthcare
Denials didn't get better in 2025. They got worse – and the data shows exactly where, why, and by how much. Every RCM leader has a gut sense that denials are climbing. What's harder to find is a single place that pulls together what the national numbers actually say: how much revenue is on the line, which denial types are driving the increase, what prior authorization is doing to physicians and patients, and how much of this is actually fixable with the automation and AI tools available today.This report pulls from the primary sources that matter – Kodiak Solutions' benchmarking data, the American Hospital Association, CMS's own prior authorization disclosures, the AMA's physician survey, and the CAQH Index – to build that single reference point.
.png)
.png)
The State of Claim Denials in U.S. Healthcare
Denials didn't get better in 2025. They got worse – and the data shows exactly where, why, and by how much. Every RCM leader has a gut sense that denials are climbing. What's harder to find is a single place that pulls together what the national numbers actually say: how much revenue is on the line, which denial types are driving the increase, what prior authorization is doing to physicians and patients, and how much of this is actually fixable with the automation and AI tools available today.This report pulls from the primary sources that matter – Kodiak Solutions' benchmarking data, the American Hospital Association, CMS's own prior authorization disclosures, the AMA's physician survey, and the CAQH Index – to build that single reference point.
.png)
.png)
.png)
.png)
XiFin - 101 Guide
When a private equity firm holds a healthcare technology company for twelve years–nearly double the industry standard–it tells a story. Whether that narrative speaks to product maturity or exit market challenges remains an open question, and one that diagnostic billing leaders should answer before signing multi-year contracts with XiFin. This article is exactly about this.